Phase IB study of TNT009 in patients with Cold Agglutinin Disease
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs BIVV-009 (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions
- 11 Dec 2017 According to a Bioverativ media release, primary and secondary outcome measures were achieved in the six patients with primary CAgD in the study.
- 11 Dec 2017 According to a Bioverativ media release, six primary CAgD patients data was presented at the 59th Annual Meeting of the American Hematology Society.
- 11 Dec 2017 Results (n=6) presented in a Bioverativ media release.